133 related articles for article (PubMed ID: 24007859)
21. Synthesis and biological evaluation of 4'-[(benzimidazole-1-yl)methyl]biphenyl-2-sulfonamide derivatives as dual angiotensin II/endothelin A receptor antagonists.
Bai R; Wei Z; Liu J; Xie W; Yao H; Wu X; Jiang J; Wang Q; Xu J
Bioorg Med Chem; 2012 Aug; 20(15):4661-7. PubMed ID: 22750010
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis, and biological evaluation of AT1 angiotensin II receptor antagonists based on the pyrazolo[3,4-b]pyridine and related heteroaromatic bicyclic systems.
Cappelli A; Nannicini C; Gallelli A; Giuliani G; Valenti S; Mohr Gl; Anzini M; Mennuni L; Ferrari F; Caselli G; Giordani A; Peris W; Makovec F; Giorgi G; Vomero S
J Med Chem; 2008 Apr; 51(7):2137-46. PubMed ID: 18318468
[TBL] [Abstract][Full Text] [Related]
23. Ligand-supported homology modeling of the human angiotensin II type 1 (AT(1)) receptor: insights into the molecular determinants of telmisartan binding.
Patny A; Desai PV; Avery MA
Proteins; 2006 Dec; 65(4):824-42. PubMed ID: 17034041
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis, and pharmacological evaluation of 5-oxo-1,2,4-oxadiazole derivatives as AT1 antagonists with antihypertension activities.
Zhu W; Bao X; Ren H; Liao P; Zhu W; Yan Y; Wang L; Chen Z
Clin Exp Hypertens; 2016; 38(5):435-42. PubMed ID: 27362285
[TBL] [Abstract][Full Text] [Related]
25. Rational design, efficient syntheses and biological evaluation of N,N'-symmetrically bis-substituted butylimidazole analogs as a new class of potent Angiotensin II receptor blockers.
Agelis G; Resvani A; Koukoulitsa C; Tůmová T; Slaninová J; Kalavrizioti D; Spyridaki K; Afantitis A; Melagraki G; Siafaka A; Gkini E; Megariotis G; Grdadolnik SG; Papadopoulos MG; Vlahakos D; Maragoudakis M; Liapakis G; Mavromoustakos T; Matsoukas J
Eur J Med Chem; 2013 Apr; 62():352-70. PubMed ID: 23376252
[TBL] [Abstract][Full Text] [Related]
26. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers.
Kakuta H; Sudoh K; Sasamata M; Yamagishi S
Int J Clin Pharmacol Res; 2005; 25(1):41-6. PubMed ID: 15864875
[TBL] [Abstract][Full Text] [Related]
27. Novel O-[(11)C]methylated derivatives of candesartan as angiotensin II AT(1) receptor imaging ligands: radiosynthesis and ex vivo evaluation in rats.
Hadizad T; Kirkpatrick SA; Mason S; Burns K; Beanlands RS; Dasilva JN
Bioorg Med Chem; 2009 Dec; 17(23):7971-7. PubMed ID: 19879152
[TBL] [Abstract][Full Text] [Related]
28. Design and synthesis of new tetrazolyl- and carboxy-biphenylylmethyl-quinazolin-4-one derivatives as angiotensin II AT1 receptor antagonists.
Ismail MA; Barker S; Abou el-Ella DA; Abouzid KA; Toubar RA; Todd MH
J Med Chem; 2006 Mar; 49(5):1526-35. PubMed ID: 16509571
[TBL] [Abstract][Full Text] [Related]
29. Structural insight on the activity of type 1 angiotensin II peptide antagonists using MD simulations.
Preto MA; Melo A; Rodrigues LM; Maia HL; Ramos MJ
J Phys Chem B; 2008 Oct; 112(43):13620-8. PubMed ID: 18834172
[TBL] [Abstract][Full Text] [Related]
30. Revelation on the potency of α(1) -blockers - parallel blockade of angiotensin II receptor: a new finding.
Yadav MR; Gandhi HP; Naik PP; Giridhar R
Pharm Biol; 2012 Apr; 50(4):439-42. PubMed ID: 22136253
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis and evaluation of novel potent angiotensin II receptor 1 antagonists.
Bao X; Zhu W; Yuan W; Zhu X; Yan Y; Tang H; Chen Z
Eur J Med Chem; 2016 Nov; 123():115-127. PubMed ID: 27474928
[TBL] [Abstract][Full Text] [Related]
32. Substituted benzimidazole derivatives as angiotensin II-AT1 receptor antagonist: a review.
Vyas VK; Ghate M
Mini Rev Med Chem; 2010 Dec; 10(14):1366-84. PubMed ID: 20937029
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and evaluation of the novel 2-[¹⁸F]fluoro-3-propoxy-triazole-pyridine-substituted losartan for imaging AT₁ receptors.
Arksey N; Hadizad T; Ismail B; Hachem M; Valdivia AC; Beanlands RS; deKemp RA; DaSilva JN
Bioorg Med Chem; 2014 Aug; 22(15):3931-7. PubMed ID: 25023539
[TBL] [Abstract][Full Text] [Related]
34. Development of CoMFA models of affinity and selectivity to angiotensin II type-1 and type-2 receptors.
Sköld C; Karlén A
J Mol Graph Model; 2007 Jul; 26(1):145-53. PubMed ID: 17161636
[TBL] [Abstract][Full Text] [Related]
35. Binding sites of valsartan, candesartan and losartan with angiotensin II receptor 1 subtype by molecular modeling.
Bhuiyan MA; Ishiguro M; Hossain M; Nakamura T; Ozaki M; Miura S; Nagatomo T
Life Sci; 2009 Jul; 85(3-4):136-40. PubMed ID: 19446572
[TBL] [Abstract][Full Text] [Related]
36. Distinct properties of telmisartan on agonistic activities for peroxisome proliferator-activated receptor γ among clinically used angiotensin II receptor blockers: drug-target interaction analyses.
Kakuta H; Kurosaki E; Niimi T; Gato K; Kawasaki Y; Suwa A; Honbou K; Yamaguchi T; Okumura H; Sanagi M; Tomura Y; Orita M; Yonemoto T; Masuzaki H
J Pharmacol Exp Ther; 2014 Apr; 349(1):10-20. PubMed ID: 24424487
[TBL] [Abstract][Full Text] [Related]
37. 2,3-Dihydro-2-oxo-1H-benzimidazole-1-carboxamides with selective affinity for the 5-HT(4) receptor: synthesis and structure-affinity and structure-activity relationships of a new series of partial agonist and antagonist derivatives.
Tapia I; Alonso-Cires L; López-Tudanca PL; Mosquera R; Labeaga L; Innerárity A; Orjales A
J Med Chem; 1999 Jul; 42(15):2870-80. PubMed ID: 10425096
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and biological activities of novel nonpeptide angiotensin II receptor antagonists based on benzimidazole derivatives bearing a heterocyclic ring.
Guo XZ; Shi L; Wang R; Liu XX; Li BG; Lu XX
Bioorg Med Chem; 2008 Dec; 16(24):10301-10. PubMed ID: 18976926
[TBL] [Abstract][Full Text] [Related]
39. Angiotensin AT1 receptor antagonists enhance the anticonvulsant action of valproate in the mouse model of maximal electroshock.
Łukawski K; Janowska A; Jakubus T; Tochman-Gawda A; Czuczwar SJ
Eur J Pharmacol; 2010 Aug; 640(1-3):172-7. PubMed ID: 20465998
[TBL] [Abstract][Full Text] [Related]
40. Syntheses and structure-activity relationships of novel, potent, and selective trans-2-[3-oxospiro[isobenzofuran-1(3H),1'-cyclohexan]-4'-yl]benzimidazole NPY Y5 receptor antagonists.
Ogino Y; Ohtake N; Nagae Y; Matsuda K; Ishikawa M; Moriya M; Kanesaka M; Mitobe Y; Ito J; Kanno T; Ishihara A; Iwaasa H; Ohe T; Kanatani A; Fukami T
Bioorg Med Chem Lett; 2008 Sep; 18(18):4997-5001. PubMed ID: 18752943
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
